Dr. Arnold L. Oronsky has been with InterWest's life sciences team since 1994. He is a board member Amplimmune, Applied Genetic Technologies Corporation (AGTC), Arcion, Drais Pharmaceuticals, Dynavax Technologies (DVAX), Integrated Diagnostics, MacroGenics and RadioRx.

As a Ph.D. in immunology and senior lecturer at the Department of Medicine at Johns Hopkins Medical School, Dr. Oronsky brings a deep understanding of medical research to finding and investing in successful life sciences companies.

Prior to joining InterWest, Dr. Oronsky was vice president for discovery research of the Lederle Laboratories division of American Cyanamid Company where he directed the research for new drugs.

Dr. Oronsky received a Ph.D. in immunology from Columbia University and has published more than 125 articles in scientific journals.

Previous Representative Investments

Aspreva Pharmaceuticals – acquired by Galenica (GALN.SW)
Corixa – acquired by GlaxoSmithKline (GSK)
Coulter Pharmaceutical – acquired by Corixa (CRXA)
Metabasis – acquired by Ligand (LGND)
Myogen – acquired by Gilead (GILD)
Signal Pharmaceuticals – acquired by Celgene (CELG)
Salmedix – acquired by Cephalon (CEPH)

A Word from Arnie

"I came to InterWest after leading a large research organization at Lederle Laboratories. It's one thing to understand the science and its potential, but quite a different challenge to turn that science into a profitable company that meets real market and health care needs. Through my years at InterWest, I have found that my greatest challenge and greatest achievement is to marry outstanding science to outstanding management in order to build a durable, successful company."